Literature DB >> 24519954

Analysis of safety data in clinical trials using a recurrent event approach.

Qi Gong1, Barbara Tong, Alexander Strasak, Liang Fang.   

Abstract

As an important aspect of the clinical evaluation of an investigational therapy, safety data are routinely collected in clinical trials. To date, the analysis of safety data has largely been limited to descriptive summaries of incidence rates or contingency tables aiming to compare simple rates between treatment arms. Many have argued that this traditional approach failed to take into account important information including severity, onset time, and multiple occurrences of a safety event. In addition, premature treatment discontinuation due to excessive toxicity causes informative censoring and may lead to potential bias in the interpretation of safety events. In this article, we propose a framework to summarize safety data with mean frequency function and compare safety events of interest between treatments with a generalized log-rank test, taking into account the aforementioned characteristics ignored in traditional analysis approaches. In addition, a multivariate generalized log-rank test to compare the overall safety profile of different treatments is proposed. In the proposed method, safety events are considered to follow a recurrent event process with a terminal event for each patient. The terminal event is modeled by a process of two types of competing risks: safety events of interest and other terminal events. Statistical properties of the proposed method are investigated via simulations. An application is presented with data from a phase II oncology trial.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  benefit-risk assessment; informative censoring; log-rank test; mean frequency function; terminal event

Mesh:

Year:  2014        PMID: 24519954     DOI: 10.1002/pst.1611

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  2 in total

1.  Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.

Authors:  Ralf Bender; Lars Beckmann; Stefan Lange
Journal:  Pharm Stat       Date:  2016-02-29       Impact factor: 1.894

Review 2.  Statistical methods for the analysis of adverse event data in randomised controlled trials: a scoping review and taxonomy.

Authors:  Rachel Phillips; Odile Sauzet; Victoria Cornelius
Journal:  BMC Med Res Methodol       Date:  2020-11-30       Impact factor: 4.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.